Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Thoughts after the 2021 Annual meeting: Cytodyn

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155004
(Total Views: 862)
Posted On: 11/24/2021 1:24:03 PM
Posted By: grow
Thoughts after the 2021 Annual meeting:

Cytodyn has persevered through many obstacles such as:
needing to gather more HIV data for the FDA years ago,
the incompetence and harmful roadblocks of Amarex, and
the egoism & conflicts of interest from an attempted hostile board takeover.

All annual meeting ballot points were approved by the shareholders today, including an increase to the authorized shares which allows the company a tool to raise funds when needed.

Human trial data has been gathered across multiple diseases (HIV, Covid19, NASH, Breast Cancer, Colo-rectal Cancer, Pancreatic Cancer, etc. The potential for many symbiotic partnerships is strong.

The company now mentions that the scope of where the drug may be useful has increased over the years from a small segment of the HIV patient population to now 32 separate diseases including Auto-Immune conditions, Cancer, Covid19, NASH, etc. The potential drug market size has increased from $30 million to $125 Billion.

The company has wisely defended it's intellectual property, defended itself from a hostile takeover attempt, diversified it's use of CRO's, diversified it's trials into other countries, diversified it's regulatory approval into other countries, and secured production.

All these are signs of a tenacious team which continues to display that they have a fire in their belly that will bring them to the finish line IMO


(36)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us